Wednesday, 08 April 2020

AstraZeneca, BMS gets FDA nod for diabetes drug

09 January 2014 | Regulatory | By BioSpectrum Bureau

Farxiga (dapagliflozin)by AstraZeneca and Bristol-Myers Squibb has got the American drug regulatory nod

Farxiga (dapagliflozin)by AstraZeneca and Bristol-Myers Squibb has got the American drug regulatory nod

Singapore: AstraZeneca and Bristol-Myers Squibb have recieved U.S. Food and Drug Administration (FDA) approval for diabetes drug Farxiga (dapagliflozin).

AstraZeneca and Bristol-Myers Squibb are working in collaboration to develop and commercialize a portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account